IN8bio (NASDAQ:INAB) (NASDAQ: INAB) is a clinical-stage immunotherapy company dedicated to developing next-generation cell and gene therapies for patients with cancer. Leveraging proprietary platforms, the company focuses on two complementary approaches: autologous T-cell therapies designed to target and eradicate malignant cells in the brain and central nervous system, and allogeneic natural killer (NK) cell therapies aimed at a broad range of solid tumors and hematologic malignancies. IN8bio’s mission centers on harnessing the body’s own immune defenses through precision-engineered treatments that address critical unmet needs in oncology.
The company’s lead T-cell program employs a multi‐agent “shock and kill” strategy for glioblastoma, combining low-dose chemotherapeutic sensitizers with autologous T-cell infusions to enhance tumor antigen presentation and cytotoxic activity. In parallel, its NK‐cell platform utilizes a proprietary expansion and activation process to generate off-the-shelf allogeneic NK cells with robust anti-tumor functionality. This pipeline includes investigational treatments for non‐small cell lung cancer, bladder cancer, acute myeloid leukemia and multiple myeloma, with preclinical and early‐phase clinical studies underway to validate safety and efficacy.
Founded in 2020 and headquartered in Marina del Rey, California, IN8bio has established strategic collaborations with leading academic institutions and research centers to accelerate its therapeutic development. The company’s partnerships enable access to specialized clinical expertise, innovative manufacturing capabilities and translational research programs. While its initial focus is on patients in North America, IN8bio is positioned to expand its global footprint through future regulatory filings and international clinical trials.
IN8bio’s leadership team brings together seasoned professionals from the biotechnology, pharmaceutical and healthcare sectors. Chief Executive Officer Amir Nashat, Ph.D., leads the company’s strategic vision, supported by executives with extensive experience in cell therapy development, regulatory affairs and commercial planning. Guided by a board of directors with deep domain knowledge of immuno-oncology, IN8bio is committed to advancing safe and effective treatments that improve outcomes for cancer patients worldwide.
